{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"2"}],"units":"Participants"}],"description":"Number of HGG patients with radiographic response by study part, schema, and dose level.","groups":[{"description":"35 mg/m\\^2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) of a 28 day, or 8 dose course (Pre-amendment #1)","id":"OG000","title":"Part A: Dose Level 1"},{"description":"35 mg/m\\^2 of Selinexor PO twice weekly on a days 1 and 3 schedule (Mon/Wed, Tues/Thurs, or Wed/Fri) on Weeks 1-3, Week 4 rest, on a 28 day course (Amendment 1)","id":"OG001","title":"Part A: Dose Level 1 (DL 1)"},{"description":"45 mg/m\\^2 Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","id":"OG002","title":"Part A: Weekly Dose Level 1 (WDL 1)"},{"description":"35 mg/m2 Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","id":"OG003","title":"Part A: Weekly Dose Level -1 (WDL -1)"},{"description":"35 mg/m\\^2 Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","id":"OG004","title":"Part B: Weekly Dose Level -1 (WDL -1)"},{"description":"35 mg/m\\^2 Selinexor once weekly, on days 1, 8, 15, and 22 of a 28-day cycle","id":"OG005","title":"Part PK: Weekly Dose Level -1 (WDL -1)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"high-grade glioma (HGG) patients","reportingStatus":"POSTED","timeFrame":"Up to 6 years 11 months","title":"Radiographic Response of Selinexor in High-grade Glioma (HGG) Patients","type":"SECONDARY","unitOfMeasure":"Participants"}